Q1 2026 Syndax Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Syndax Pharmaceuticals Inc (SNDX) reported over $100 million in combined sales of Revuforj and Niktimvo, indicating strong demand and progress towards profitability.
- Revuforj net revenue grew by double-digits quarter over quarter, driven by new NPM-1 patients and strong adoption across indications.
- Niktimvo delivered $55 million in net revenue in the first quarter, reflecting consistent new patient starts and strong commercial synergies.
- The company is well-positioned to be the first to get a menin inhibitor approved in frontline AML, with strong global site activation and patient enrollment underway.
- Syndax Pharmaceuticals Inc (SNDX) is well-funded with $352.1 million in cash equivalents and marketable securities, supporting continued investment in commercialization and development.
- The robust transplant rates seen with Revuforj have a short-term impact on the business, as many patients pause treatment to proceed to transplant.
- Natural attrition among the large cohort of later-line patients who started Niktimvo during the first quarter of launch last year partially offset new patient starts.
- The company faces competition in the menin inhibitor market, which could impact market share and revenue growth.
- There is a delay in patients returning to therapy post-transplant, with some taking six months or more to restart, affecting revenue timing.
- Gross to net adjustments impacted year-over-year growth, with typical first-quarter seasonality affecting financial results.
Good day, everyone, and welcome to the Syndax first quarter 2026 earnings conference call. Today's call is being recorded. (Operator Instructions)
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's first quarter 2026 financial and operating results. I'm Sharon Clary, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Steve Closter, Chief Commercial Officer; Dr. Nick Botwood Head of R&D and Chief Medical Officer; and Keith Goldan, Chief Financial Officer. This call is accompanied by a slide deck that has been posted on the investor page of the company's website. You can now turn to our forward-looking statements on slide 2.
Before we begin, I'd like to remind you that any statements made during this call that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
